Drug

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA
ADC / XDCKelun Pharmaceutical

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that a new indication application for sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) has been accepted for review by the Center for…

Joincare's LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Joincare’s LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Hengrui's Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Hengrui’s Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Phanes Therapeutics Doses First Patient in CD73 Antibody Clinical Study
CancerClinical trial approval / initiation

Phanes Therapeutics Doses First Patient in CD73 Antibody Clinical Study

StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment
Gene therapyOphthalmology

StarryGene Initiates Phase II Study of XMVA09 for Wet AMD Treatment

Eisai's Dayvigo Granted NMPA Approval for Insomnia Treatment
EisaiProduct approvals

Eisai’s Dayvigo Granted NMPA Approval for Insomnia Treatment

BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients
AmgenBeiGene

BeiGene and Amgen Report Positive Results for Tarlatamab in Chinese ES-SCLC Patients

Show More